Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DVL1 | O14640 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834072 | 0.92 | ALDH1A1 (0.41) | PARP14LMNAALDH1A1NSD2KDM4E | |
| SCHEMBL6834504 | 0.92 | LMNA (0.47) | PARP14LMNAALDH1A1KDM4EPKM | |
| SCHEMBL6833821 | 0.90 | NHERF1 (0.43) | PARP14KCNQ2LMNAKDM4EALB | |
| SCHEMBL6833973 | 0.90 | PARP14 (0.42) | PARP14KCNQ2LMNAPKMALB | |
| SCHEMBL6833069 | 0.89 | POLB (0.48) | PARP14KCNQ2LMNAALDH1A1KDM4E | |
| SCHEMBL6834298 | 0.89 | MEN1 (0.44) | PARP14LMNAALDH1A1KDM4EPKM | |
| SCHEMBL6830257 | 0.88 | RXFP1 (0.48) | PARP14KCNQ2MEN1KMT2AMAPK8 | |
| SCHEMBL6818890 | 0.87 | TRPV1 (0.46) | PARP14KCNQ2LMNAKDM4EALB | |
| SCHEMBL6833683 | 0.87 | NR1H4 (0.48) | ALDH1A1 | |
| SCHEMBL6835671 | 0.87 | LMNA (0.39) | PARP14LMNAPKMALBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | PARP14 2395/4885KCNQ2 2555/4885LMNA 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.